- Policy
- Reformed listing procedure requires generic to negotiate
- by Kim, Jung-Ju Mar 25, 2020 06:02am
- The Korean government is ready to finalize a legal basis requiring generic drugs to negotiate and sign a compliance agreement with the government and insurer. Currently, generics are listed for reimbursement comparatively easier than the drugs taking the regular pricing track,. Also, the legal basis would stipulate the government to lega
- Product
- Who will succeed in COVID-19 treatment?
- by choi-sun Mar 25, 2020 06:01am
- As pharmaceutical companies around the world are plunging into the development of vaccines and treatments for COVID-19 treatment, attention is focused on who will succeed in commercialization. Among the treatments, Gilead Sciences entered Phase III of clinical trials, and in the field of vaccines, it entered Phase I by Moderna Therapeutics. H
- Policy
- Coxib-tramadol pain reliever readies commercialization
- by Lee, Tak-Sun Mar 24, 2020 05:21am
- Commercialization for a combination drug based on anti-inflammatory coxib and tramadol is in currently in development. The pharmaceutical industry anticipates it would be the next generation pain reliever with improved effect. According to the industry, coxib-tramadol hydrochloride combination drug is preparing for a launch. On Mar.
- Company
- Jina Lee at Bayer stepped up as CEO of Thai Corporation
- by Eo, Yun-Ho Mar 24, 2020 05:20am
- Jina Lee, Health BU Head at Bayer, will be represented as the CEO of Thai corporation. Bayer Korea recently announced in its internal announcement that Jina Lee will be appointed as the CDH (Country Division Head) of the Thai Pharmaceutical Division. However, due to the aftermath of COVID-19, the exact departure schedule and the like have
- Policy
- Asan Medical Center to test Kaletra's effect on COVID-19
- by Lee, Tak-Sun Mar 24, 2020 05:19am
- An investigator-sponsored trial (IST) in Korea is in preparation to confirm efficacy of Kaletra and hydroxychloroquine in patients with mild case of COVID-19. On Mar. 20, Korea’s Ministry of Food and Drug Safety (MFDS) has granted an approval on an IST protocol submitted by Seoul Asan Medical Center. The protocol is on open-label, r
- Company
- Multinational Pharmaceuticals, COVID-19 Relief Goods
- by Eo, Yun-Ho Mar 24, 2020 05:19am
- Multinational pharmaceutical companies make donations to overcome COVID-19 crisis. According to the related industry, Korean corporations from multinational pharmaceutical companies such as Novartis, Mundipharma, Bayer, and Ferring, including the Korean Research-based Pharma Industry Association (KRPIA), have supported donations and relief
- Policy
- DNA vaccine for COVID-19, what are the complications?
- by Lee, Tak-Sun Mar 24, 2020 05:19am
- As the U.S. and China have initiated their clinical trials on COVID-19 vaccines, the public is keen on when Korea would start its vaccine commercialization process. The vaccine currently in the clinical trial phase is a DNA vaccine. The type of vaccine is developed by artificially replicating a part of infectious agent, which makes the d
- Policy
- Price of Roche's Herceptin 150mg (Trastuzumab) falls 8.1%
- by Kim, Jung-Ju Mar 24, 2020 05:18am
- Korea Roche's blockbuster anticancer drug Herceptin 150mg (Trastuzumab) is being added, and the insurance premium will be reduced by more than 8% starting next month. Nelson Pharm's Bedesta cream and Ahn-gook Pharm's Saerogenta cream fell 25.4% each due to governmental adjustment. There are a total of 23 drugs falling due to authority adjustm
- Company
- Listed ovarian anticancer Zejula applies for new indications
- by Eo, Yun-Ho Mar 23, 2020 06:28am
- Anticancer treatment Zejula, listed for pharmaceutical reimbursement last year, is now preparing for expanded label. According to related industry on Mar. 23, Takeda Pharmaceuticals Korea has recently submitted an application to expand reimbursement on DNA repairing Poly ADP-ribose Polymerase (PARP) inhibitor Zejula (niraparib). The
- Policy
- Neutropenia is common in children when taking Entecavir
- by Lee, Tak-Sun Mar 23, 2020 06:27am
- The MFDS has begun to change the license because there have been reports of Neutropenia in pediatric clinical trials of Entecavir, one of hepatitis B treatment. Neutrophils are a type of white blood cells that are granulocytes responsible for the body's immunity. The MFDS announced on the 20th that it is reported that Neutropenia is ver
